Len/Ev RCC....Flat

Discussion in 'Eisai' started by anonymous, Mar 1, 2017 at 12:40 PM.

Tags: Add Tags
  1. anonymous

    anonymous Guest

    Not surprising but Len/Ev is not flying off the shelfs...4th line at best. Can't we ever have a good product to sell??? This place sucks!
     

  2. anonymous

    anonymous Guest

    Maybe I would be fine with a 4th line product if the goals were realistic. Our goals are paced like we are selling Opdivo or Keytruda. Dude is 4th line combo chemo at 24k a month squeezed out by contractors. And now they are acting like HCC will change the world.

    How about some realistic goals do a rep can show growth and actually earn a bonus.
     
  3. anonymous

    anonymous Guest

    Small phase 2 study, high toxicity, not any better than the other single agent 2L products who have P3 data, no "preferred" status with NCCN. Sure go out and knock off Nivo and Cabo. The challenger model will get us there!!! Our customers hate this combo. Medically and financially toxic.
     
  4. anonymous

    anonymous Guest

    The goals are very unrealistic and so is the way they calculate quotas. You can go from zero to hero, back to zero again, in just a few quarters.